The Sonolith i-move is a compact and modular lithotripter with an infrared stereo-vision system for real-time, three-dimensional ultrasound free line localization of urinary stones.
The Sonolith i-move offers a wide range of treatment procedures for clinical sites and hospitals with its various and flexible configurations.
EDAP said its patented and electro-conductive technology has proved successful and demonstrated the highest efficiency rates, thus definitely bringing significant benefits to patients and users.
EDAP CEO Marc Oczachowski said the approval of their new Sonolith i-move by the Korean FDA is another step forward in introducing their Sonolith i-move technology in major markets worldwide.
"It also confirms our capacity to navigate approval processes in various countries to further maintain our leading position in major lithotripsy markets," Oczachowski said.
"As we successfully advance in our regulatory milestones, we continue to make progress in view of approval of our Sonolith i-move device by Japanese authorities and US FDA."
